SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY) announced final results from the Phase III AVAglio study in people with newly diagnosed glioblastoma, the most common form of primary brain cancer. The company said final results confirmed people who received Avastin plus radiotherapy and temozolomide chemotherapy benefited from a significant improvement in progression-free survival compared to those who received placebo plus radiotherapy and temozolomide chemotherapy. Overall survival was not significantly improved in the study.
Avastin is currently approved in the United States under the FDA accelerated approval program for the treatment of adults with glioblastoma who have progressive disease following prior therapy. In recurrent glioblastoma, it is approved for use as a single therapy and not in combination with other therapies.
AVAglio is a Phase III, randomized, double-blind, placebo controlled trial that assessed the efficacy and safety profile of Avastin in combination with radiotherapy and temozolomide chemotherapy following surgery or biopsy in patients with newly diagnosed glioblastoma.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de